Bio-Rad Laboratories | BIO - Current Liabilities


Bio-Rad Laboratories reported $969.1M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Abbott USD 16.15B 1.66B Sep/2026
Agilent USD 2.29B 20M Jun/2026
Becton, Dickinson and Co. USD 9.54B 139M Sep/2026
Bio Techne USD 361.27M 197.57M Sep/2026
Bio-Rad Laboratories USD 969.1M 7.8M Sep/2026
Bruker USD 1.17B 32.6M Sep/2026
Charles River Laboratories USD 1.09B 45.49M Sep/2026
Danaher USD 9.05B 945M Sep/2026
General Electric Aerospace USD 42.4B 1.96B Sep/2026
Illumina USD 1.16B 422M Sep/2026
IQVIA Holdings USD 7.78B 1.04B Sep/2026
Laboratory Of America USD 2.82B 695M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Mettler Toledo International USD 1.25B 49.81M Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
OraSure Technologies USD 25.12M 18.96M Jun/2026
Pacific Biosciences Of California USD 66.59M 2.21M Sep/2026
Quest Diagnostics USD 1.83B 46M Sep/2026
Repligen USD 125.69M 6.97M Sep/2026
Revvity USD 701.48M 574.88M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Siemens EUR 47.56B 2.45B Sep/2026
Standard Biotools USD 51.02M 5.78M Sep/2026
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Tosoh JPY 404.7B 12.78B Sep/2026
Waters USD 2.4B 126M Jun/2026